Stock Track | Edgewise Therapeutics Soars in Premarket After Beating Q3 Earnings Estimates

Stock Track

Nov 07, 2024

Shares of Edgewise Therapeutics, Inc. (EWTX) are surging in premarket trading on Tuesday, up over 9% after the biopharmaceutical company reported better-than-expected earnings results for the third quarter of 2024.

For the quarter ended September 30, Edgewise reported a loss of $0.36 per share, narrowly beating analyst expectations of a $0.37 per share loss. The company did not generate any revenue during the quarter, which was in line with forecasts.

While Edgewise continues to operate at a loss as it develops its pipeline of therapeutics, the earnings beat has fueled investor optimism and driven the stock higher in premarket trading. The strong performance follows a 37.2% gain for EWTX shares during the third quarter and a remarkable 234.7% increase so far this year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1104969865"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1104969865\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1104969865?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 23:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104969865","market":"us","top_or_hot":-1,"title":"Stock Track | Edgewise Therapeutics Soars in Premarket After Beating Q3 Earnings Estimates","media":"Stock Track","content":"<p>Shares of Edgewise Therapeutics, Inc. (EWTX) are surging in premarket trading on Tuesday, up over 9% after the biopharmaceutical company reported better-than-expected earnings results for the third quarter of 2024.</p>\n\n<p>For the quarter ended September 30, Edgewise reported a loss of $0.36 per share, narrowly beating analyst expectations of a $0.37 per share loss. The company did not generate any revenue during the quarter, which was in line with forecasts.</p>\n\n<p>While Edgewise continues to operate at a loss as it develops its pipeline of therapeutics, the earnings beat has fueled investor optimism and driven the stock higher in premarket trading. The strong performance follows a 37.2% gain for EWTX shares during the third quarter and a remarkable 234.7% increase so far this year.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Edgewise Therapeutics Soars in Premarket After Beating Q3 Earnings Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Edgewise Therapeutics Soars in Premarket After Beating Q3 Earnings Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-07 23:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Edgewise Therapeutics, Inc. (EWTX) are surging in premarket trading on Tuesday, up over 9% after the biopharmaceutical company reported better-than-expected earnings results for the third quarter of 2024.</p>\n\n<p>For the quarter ended September 30, Edgewise reported a loss of $0.36 per share, narrowly beating analyst expectations of a $0.37 per share loss. The company did not generate any revenue during the quarter, which was in line with forecasts.</p>\n\n<p>While Edgewise continues to operate at a loss as it develops its pipeline of therapeutics, the earnings beat has fueled investor optimism and driven the stock higher in premarket trading. The strong performance follows a 37.2% gain for EWTX shares during the third quarter and a remarkable 234.7% increase so far this year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EWTX","symbol_name":"Edgewise Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1104969865","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104969865","pubTimestamp":1730991688,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Edgewise Therapeutics, Inc.  are surging in premarket trading on Tuesday, up over 9% after the biopharmaceutical company reported better-than-expected earnings results for the third quarter of 2024.For the quarter ended September 30, Edgewise reported a loss of $0.36 per share, narrowly beating analyst expectations of a $0.37 per share loss. The company did not generate any revenue during the quarter, which was in line with forecasts.While Edgewise continues to operate at a loss as it ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EWTX":"Edgewise Therapeutics, Inc."},"translate_title":"Edgewise Therapeutics第三季度盈利超出预期后盘前股价飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWTX":1},"content_text":"Shares of Edgewise Therapeutics, Inc. (EWTX) are surging in premarket trading on Tuesday, up over 9% after the biopharmaceutical company reported better-than-expected earnings results for the third quarter of 2024.\nFor the quarter ended September 30, Edgewise reported a loss of $0.36 per share, narrowly beating analyst expectations of a $0.37 per share loss. The company did not generate any revenue during the quarter, which was in line with forecasts.\nWhile Edgewise continues to operate at a loss as it develops its pipeline of therapeutics, the earnings beat has fueled investor optimism and driven the stock higher in premarket trading. The strong performance follows a 37.2% gain for EWTX shares during the third quarter and a remarkable 234.7% increase so far this year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}